filovirus
envelop
singlestrand
negativesens
rna
virus
famili
filovirida
compris
three
genera
ebolaviru
marburgviru
ebolavirus
marburgvirus
caus
sever
human
diseas
mortal
rate
cuevaviru
found
bat
whether
infecti
human
remain
unknown
ebola
viru
ebov
speci
zair
ebolaviru
frequent
erupt
filoviru
caus
ebov
epidem
west
africa
result
suspect
case
confirm
etiolog
ebola
viru
diseas
remain
unclear
new
case
appear
may
although
vaccin
drug
studi
shown
still
licens
antifiloviru
agent
avail
filovirus
select
agent
list
world
health
organ
risk
group
pathogen
live
viru
research
requir
limit
develop
antifiloviru
vaccin
drug
aim
establish
sequenti
vitro
vivo
filoviru
entri
inhibitor
evalu
system
could
perform
facil
safeti
pseudoviru
base
hivcor
power
model
highli
pathogen
envelop
viral
entri
studi
vitro
filoviru
highli
pathogen
influenza
viru
sever
acut
respiratori
syndrom
coronaviru
middl
east
respiratori
syndrom
coronaviru
etc
bioluminesc
imag
assay
visual
tool
use
viral
studi
anim
although
ebola
viruslik
particl
use
vaccin
studi
vivo
best
knowledg
studi
compar
vivo
pharmacodynam
filoviru
entri
inhibitor
differ
genera
filovirus
studi
construct
nine
pseudofilovirus
cover
filoviru
genera
screen
filoviru
entri
inhibitor
vitro
success
establish
three
vivo
mous
infect
model
filoviru
entri
inhibitor
evalu
use
pseudotyp
ebov
marburg
viru
marv
lloviu
viru
llov
repres
virus
robust
evalu
system
confirm
assess
two
known
filoviru
entri
inhibitor
clomiphen
sequenti
vitro
vivo
filoviru
entri
inhibitor
evalu
system
condit
provid
power
technic
support
develop
broadspectrum
antifiloviru
agent
human
embryon
kidney
cell
obtain
american
type
cultur
collect
maintain
dulbecco
modifi
eagl
medium
dmem
supplement
fetal
bovin
serum
invitrogen
cell
cultur
codon
optim
glycoprotein
gene
gp
ebov
speci
zair
ebolaviru
gene
access
sudan
viru
speci
sudan
ebolaviru
gene
access
marv
speci
marburg
marburgviru
gene
access
ravn
viru
speci
marburg
marburgviru
gene
access
llov
speci
lloviu
cuevaviru
gene
access
synthes
insert
vector
tsingk
biotech
beij
china
gp
gene
ebov
speci
zair
ebolaviru
gene
access
bundibugyo
viru
speci
bundibugyo
ebolaviru
gene
access
forest
viru
tafvcot
speci
forest
ebolaviru
gene
access
reston
viru
speci
reston
ebolaviru
gene
access
insert
pcmv
vector
purchas
sino
biolog
inc
envdefici
hivluc
plasmid
contain
luciferas
report
gene
obtain
nation
institut
health
aid
research
refer
reagent
program
germantown
md
pseudofilovirus
produc
previous
briefli
plasmid
encod
filovirusgp
hiv
vector
cotransfect
ratio
produc
cell
cultur
dish
use
jetprim
transfect
reagent
accord
manufactur
protocol
polyplustransfect
fortyeight
hour
posttransfect
hivfilovirusgp
pseudovirion
contain
cell
cultur
supernat
collect
filter
pore
size
filter
millipor
vivo
studi
pseudovirus
layer
onto
cushion
wv
sucros
centrifug
rpm
h
beckman
rotor
pellet
pseudovirus
resuspend
icecold
nte
buffer
mmoll
tri
mmoll
nacl
mmoll
edta
ph
store
use
protein
viral
particl
detect
elisa
kit
sino
biolog
inc
accord
manufactur
protocol
cell
seed
plate
densiti
cellswel
h
cell
infect
pseudovirion
fortyeight
hour
postinfect
cell
lyse
luciferas
activ
measur
use
luminomet
berthold
detect
system
luciferas
assay
kit
promega
detect
vitro
antifiloviru
activ
clomiphen
citrat
ca
sigma
aldrich
toremiphen
citrat
ca
meilun
inc
cell
incub
variou
concentr
compound
threefold
dilut
min
prior
infect
incub
pseudovirus
h
luciferas
activ
dmso
solvent
control
use
infect
indic
inhibitori
concentr
compound
calcul
experi
repeat
three
time
six
eightweekold
femal
balbc
mice
beij
hfk
bioscienc
co
ltd
beij
china
hous
rais
specif
pathogenfre
anim
facil
institut
materia
medica
pumc
cam
beij
china
anim
research
perform
accord
relev
guidelin
regul
approv
institut
anim
care
use
committe
institut
materia
medica
pumc
cam
beij
china
anim
randomli
group
anim
experiment
blind
studi
investig
blind
personnel
perform
intraperiton
inject
pseudoviru
solut
mice
mous
inocul
ml
pseudoviru
solut
compound
activ
experi
mice
intraperiton
ip
administ
differ
concentr
compound
dissolv
inject
dose
mlkg
time
point
indic
mice
solvent
control
group
administ
simultan
drug
group
day
day
h
prechalleng
viral
challeng
pseudoviru
stock
dilut
dmem
indic
infect
dose
administ
ip
inject
volum
mlmous
anim
bioluminesc
monitor
time
point
indic
bodi
weight
mice
record
daili
bioluminesc
imag
test
complet
bioluminesc
imag
mice
conduct
use
ivi
spectrum
ct
imag
system
perkinelm
briefli
mous
inject
ip
ml
mgml
solut
dluciferin
potassium
salt
substrat
xenolight
perkinelm
anesthet
isofluran
two
five
minut
inject
substrat
bioluminesc
signal
acquir
mice
anesthet
imag
nosecon
deliveri
isofluran
quantifi
number
photon
emit
mice
whole
bodi
individu
mous
manual
defin
region
interest
roi
rel
bioluminesc
shown
total
flux
photonssecond
calcul
use
live
imag
softwar
calip
life
scienc
data
express
mean
sem
standard
error
mean
sd
standard
deviat
statist
analys
comparison
two
group
perform
unpair
student
ttest
use
graphpad
prism
softwar
statist
signific
set
p
valu
p
valu
indic
signific
p
valu
indic
signific
p
valu
indic
extrem
signific
filoviru
famili
ebov
sudv
bdbv
tafv
restv
member
belong
five
speci
ebolaviru
genu
restv
caus
asymptomat
infect
four
ebolavirus
caus
sever
fatal
hemorrhag
fever
human
marburgviru
genu
contain
one
speci
marburg
marburgviru
includ
marv
ravv
cuevaviru
genu
contain
one
speci
lloviu
cuevaviru
one
member
llov
filovirus
glycoprotein
gp
viral
compon
respons
entri
phylogenet
relationship
filovirusgp
shown
fig
studi
prepar
nine
hivbas
pseudofilovirus
cover
speci
filoviru
pseudovirus
produc
cotransfect
hivcor
contain
firefli
luciferas
gene
filovirusgp
express
plasmid
cell
packag
hivfilovirusgp
virion
viral
envelop
encas
filovirusgp
could
mediat
oneround
viral
entri
host
cell
luciferas
infect
cell
could
use
report
infect
evalu
system
besid
hivfilovirusgp
virion
hivalon
virion
envelop
glycoprotein
hivvsvg
virion
envelop
protein
vesicular
stomat
viru
glycoprotein
vsvg
also
prepar
model
control
pseudofilovirus
infect
cell
yield
log
signal
hivalon
virion
hivvsvg
virion
yield
log
signal
respect
fig
clomiphen
toremiphen
two
known
filoviru
entri
inhibitor
evalu
pseudovirus
system
valid
shown
tabl
clomiphen
filovirus
rang
toremiphen
filovirus
rang
specif
compound
confirm
hivvsvg
model
fig
result
consist
previous
report
effect
compound
live
ebolaviru
vivo
studi
viru
collect
purifi
condens
sucros
cushion
centrifug
remov
possibl
immunogen
interfer
mixtur
serumcontain
cell
cultur
media
cellular
metabolit
amount
protein
pellet
pseudovirion
quantifi
elisa
use
measur
viral
content
first
investig
infect
hivebovgp
mayinga
strain
ng
live
mice
day
postinfect
dpi
inocul
rout
mice
intraperiton
inject
rout
live
ebolaviru
mouseadapt
model
facil
shown
fig
bioluminesc
mice
infect
hivebovgp
could
observ
uninfect
control
mice
hivalon
virioninfect
mice
show
bioluminesc
photon
flux
collect
hivebovgpinfect
mice
show
signific
differ
p
collect
uninfect
control
mice
fig
strongest
bioluminesc
region
mice
upper
chest
bioluminesc
imag
indic
bioluminesc
hivebovgpinfect
mice
mainli
accumul
thymu
fig
bioluminesc
hivmarvgp
hivllovgpinfect
mice
monitor
shown
fig
two
pseudofilovirus
could
also
effect
infect
mice
bioluminesc
local
mice
ident
hivebovgp
group
pseudofilovirusinfect
mice
show
chronolog
bioluminesc
increas
intens
reach
peak
valu
intens
gradual
descend
time
point
bioluminesc
pseudofilovirusinfect
mice
reach
peak
differ
slightli
hivebovgp
hivmarvgp
group
peak
appear
around
h
postinfect
hpi
ie
dpi
hivllovgp
group
peak
appear
around
hpi
ie
dpi
addit
hivebovgpinfect
mice
show
higher
peak
intens
bioluminesc
hivmarvgp
hivllovgp
group
ng
dose
order
obtain
ident
vivo
viral
infect
level
among
pseudofilovirus
viral
dose
ng
hivebovgp
viru
show
compar
bioluminesc
intens
ng
hivmarvgp
hivllovgp
infect
use
assess
vivo
activ
antifiloviru
compound
determin
whether
inocul
viral
dose
correl
bioluminesc
valu
infect
mice
linear
regress
analysi
carri
total
photon
flux
mice
hivebovgp
viral
dose
shown
fig
bioluminesc
hivebovgpinfect
mice
show
strong
linear
correl
viral
dose
linear
bioluminescencedos
correl
also
observ
hivmarvgp
hivllovgpinfect
mice
data
shown
result
indic
hivfilovirusgp
infect
mous
model
could
provid
accur
assess
viral
infect
live
mice
valid
vivo
model
mice
pretreat
differ
dose
clomiphen
toremiphen
mgkg
bodi
weight
ip
daili
h
dpi
control
mice
administ
solvent
solut
simultan
compound
group
day
mice
ip
challeng
hivfilovirusgp
virion
ng
hivebovgp
ng
hivmarvgp
ng
hivllovgp
ml
dmem
bioluminesc
mice
examin
hpi
hivebovgp
hivmarvgp
group
hpi
hivllovgp
group
shown
fig
bioluminesc
clomiphen
toremiphenetr
group
present
dosedepend
inhibit
hivebovgp
hivmarvgp
hivllovgp
viral
infect
specif
two
drug
also
confirm
inabl
inhibit
hivvsvg
viru
vivo
data
shown
result
show
pseudofiloviru
mous
model
use
vivo
pharmacodynam
evalu
antifiloviru
compound
ebolavirus
marburgvirus
discov
respect
neither
antifiloviru
drug
vaccin
approv
hand
sever
agent
report
effect
filoviru
infect
test
vivo
partial
due
facil
restrict
infect
host
cell
hivbas
pseudoviru
singl
round
infect
mediat
gpreceptor
express
luciferas
report
gene
infect
cell
organ
conveni
use
quantifi
infect
featur
make
pseudovirus
highli
secur
effici
model
drug
evalu
among
anim
model
mouseadapt
model
wide
use
primari
identif
antivir
drug
easi
oper
low
cost
therefor
studi
establish
pseudofilovirusbas
vivo
mous
model
perform
facil
compound
activ
evalu
live
viru
model
one
difficulti
nonleth
characterist
wildtyp
ebolavirus
marburgvirus
immunocompet
adult
mice
multipl
round
viru
passag
conduct
assay
suckl
immunodefici
mice
obtain
lethal
mutant
mouseadapt
viru
strain
adult
mice
made
construct
live
ebolaviru
marburgviru
mous
model
moreov
also
difficult
achiev
vivo
live
viru
infect
model
viru
strain
low
pathogen
strain
could
identifi
sequenc
furthermor
mutat
site
viru
protein
mouseadapt
viru
model
might
caus
drug
candid
overlook
especi
small
compound
target
site
wildtyp
viral
protein
flaw
could
compens
pseudofiloviru
vivo
model
could
directli
use
ident
clinicallyoccur
viral
gp
gene
construct
correspond
vivo
imag
model
would
nice
reflect
featur
clinic
exist
virus
allow
quick
respons
new
type
virus
appear
establish
pseudofilovirusbas
sequenti
vitro
vivo
filoviru
entri
inhibitor
evalu
system
perform
facil
system
cover
genera
filovirus
includ
nine
pseudofiloviru
vitro
model
three
bioluminesc
imag
vivo
mous
model
verif
two
known
filoviru
entri
inhibitor
model
confirm
success
model
establish
high
safeti
effici
viabil
pseudofiloviru
model
shed
light
antifiloviru
drug
research
platform
contribut
discoveri
broadspectrum
filoviru
entri
inhibitor
